POT12 Antibody
Description
Human POT1 Antibody (Source )
Target: Protection of Telomeres 1 (POT1), a critical protein involved in telomere maintenance and genomic stability.
Product:
-
Clone: #688923
-
Antigen: Recombinant human POT1 (Met159-Pro316)
-
Application: Western blot detection in HeLa and HL-60 cell lines, yielding a band at ~60 kDa under reducing conditions.
Storage: -
Stable for 12 months at -20°C to -70°C.
-
Post-reconstitution: 1 month at 2–8°C or 6 months at -20°C to -70°C.
Table 1: Key Features of Human POT1 Antibody (MAB5299)
| Parameter | Detail |
|---|---|
| Target | POT1 (UniProt: Q9NUX5) |
| Host Species | Mouse |
| Applications | Western blotting |
| Observed Molecular Weight | ~60 kDa |
| Validation | Detected in HeLa (cervical carcinoma) and HL-60 (leukemia) cell lines |
Anti-Tspan12 Antibody (Source )
Target: Tetraspanin-12 (Tspan12), a regulator of β-catenin signaling in vascular development.
Therapeutic Role:
-
Inhibits pathological angiogenesis in retinopathy.
-
Enhances efficacy of anti-VEGF therapies (e.g., Aflibercept) in combinatorial approaches.
Mechanism: Blocks Tspan12/β-catenin signaling, reducing abnormal blood vessel growth without retinal toxicity.
General Antibody Structure and Function (Sources )
-
Fab Region: Binds antigens via variable domains (VH/VL).
-
Fc Region: Mediates immune effector functions (e.g., complement activation, opsonization).
-
Dual Functionality: Neutralization of pathogens + activation of immune responses.
Recommendations
If "POT12 Antibody" refers to a novel or less-studied target, additional context or corrected nomenclature is required to align with published research. Current data suggest potential confusion with POT1 or Tspan12, both of which are validated targets in oncology and ophthalmology, respectively. For authoritative guidance, consult primary literature or antibody databases (e.g., UniProt, R&D Systems) using precise identifiers.
Product Specs
Composition: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Here’s a curated collection of FAQs for researchers working with POT12 Antibody, structured to address both foundational and advanced academic research needs. The questions are informed by methodological best practices and antibody research principles from peer-reviewed studies:
Advanced Research Questions
How to resolve contradictory results when POT12 Antibody shows differential binding in Western blot vs. flow cytometry?
-
Troubleshooting framework:
| Factor | Western Blot | Flow Cytometry |
|---|---|---|
| Epitope conformation | Linear (denatured) | Native (3D structure) |
| Sample processing | Reducing buffer required | Non-denaturing conditions |
| Fixation artifacts | Low risk | High risk (methanol/PFA) |
-
Solution: Re-test with alternative fixation methods (e.g., paraformaldehyde vs. acetone) and confirm epitope accessibility via peptide blocking assays .
What strategies enhance POT12 Antibody signal-to-noise ratio in low-abundance target detection?
-
Optimization steps:
How to integrate POT12 Antibody with single-cell sequencing for multimodal analysis?
-
Workflow:
Data Contradiction & Reproducibility
Why does POT12 Antibody show variable neutralization efficacy across cell-based assays?
-
Analysis:
How to mitigate immunogenicity of POT12 Antibody in longitudinal animal studies?
-
Strategy:
Experimental Design Tables
Table 1: POT12 Antibody Validation Checklist
| Parameter | Method | Acceptance Criteria |
|---|---|---|
| Specificity | Knockout validation | ≥90% signal reduction in KO |
| Lot consistency | SDS-PAGE | >95% purity across batches |
| Cross-reactivity | Protein microarray | ≤5% binding to non-targets |
Table 2: OPLS Co-Formulation Protocol (From )
| Component | Concentration | Effect on Immunogenicity |
|---|---|---|
| POT12 Antibody | 1–10 µg/mL | Target-dependent |
| OPLS | 25–50 mM | Reduces IgG titers by 40–60% |
| rHuPH20 | 10 U/mL | Enhances SC bioavailability |
